RxDoctor Payments Data

Frank Wootton, MD

Gastroenterology · Norfolk, VANPI 1750366761

Payments from drug & device makers

$20,346in general payments, 2019–2025

Across 296 payments — averaging $68.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$10K
  • Adare Pharmaceuticals, Inc.$3K
  • Boehringer Ingelheim RCV GmbH & Co KG$2K
  • AbbVie$1K
  • Gilead$619
  • Takeda Pharmaceuticals U.S.A., Inc.$493
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,75299%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,346 in reported general payments places this provider in the 80th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$242,706
Medicare patients
857
Services billed
1,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$92,279
XifaxanRifaximin16$59,850
LinzessLinaclotide60$53,864
Mesalamine54$26,860
Colesevelam Hcl33$8,955
Mesalamine DrMesalamine12$3,043
Budesonide EcBudesonide12$3,024
Omeprazole171$2,675
Budesonide DrBudesonide20$2,460
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,073
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl137$1,739
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates26$1,603
Sucralfate26$1,053
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl68$1,019
Esomeprazole Magnesium26$976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$426$59,85016 claims
AbbVieLinzess$1,298$53,86460 claims
Braintree Laboratories, Inc.Sutab$98$2,07313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →